STAG3 is altered in 3.34% of all cancers with pancreatic adenocarcinoma, acute myeloid leukemia, alveolar soft part sarcoma, B-cell lymphoblastic leukemia/lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma having the greatest prevalence of alterations .
The most common alterations in STAG3 are STAG3 A424T (0.30%), STAG3 E1060K (0.30%), STAG3 E381V (0.30%), STAG3 H88Y (0.30%), and STAG3 L1006Q (0.30%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.